# Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults

> **NCT06728553** · PHASE2 · COMPLETED · sponsor: **Manistee Therapeutics** · enrollment: 78 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** MTX101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06728553
- **Lead sponsor:** Manistee Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-02-24
- **Primary completion:** 2025-06-27
- **Final completion:** 2025-07-28
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2025-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06728553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06728553, "Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06728553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*